4.7 Article

Transition to Mania During Treatment of Bipolar Depression

期刊

NEUROPSYCHOPHARMACOLOGY
卷 35, 期 13, 页码 2545-2552

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2010.122

关键词

bipolar disorder; mania; switch; antidepressant; adverse effect

资金

  1. NIMH [R01MH086026]
  2. National Institute of Mental Health (NIMH), National Institutes of Health [N01MH80001]
  3. Eli Lilly
  4. Elan/Eisai
  5. AstraZeneca
  6. Bristol-Myers Squibb
  7. Pfizer
  8. Bristol-Myers Squibb Company
  9. GlaxoSmithkline
  10. Janssen-Cilag
  11. Merck
  12. Abbott Laboratories
  13. Bristol Myers Squibb/Otsuka
  14. Ciba-Geigy
  15. Janssen Pharmaceutica
  16. Lilly Research Laboratories
  17. MacArthur Foundation
  18. National Alliance for Research in Schizophrenia and Affective Disorders
  19. Novartis
  20. Parke-Davis Pharmaceuticals
  21. Robert Wood Johnson Pharmaceutical Research Institute
  22. Sandoz Pharmaceuticals Corporation
  23. Shire Labs
  24. SmithKline Beecham Pharmaceuticals
  25. Solvay/Wyeth
  26. Stanley Medical Research Institute
  27. Solvay
  28. Tap Holdings
  29. Teva Pharmaceuticals
  30. UCB Pharma
  31. Abbott
  32. Janssen
  33. Memory Pharmaceuticals
  34. Repligen
  35. Shire
  36. Wyeth

向作者/读者索取更多资源

Some individuals with bipolar disorder transition directly from major depressive episodes to manic, hypomanic, or mixed states during treatment, even in the absence of antidepressant treatment. Prevalence and risk factors associated with such transitions in clinical populations are not well established, and were examined in the Systematic Treatment Enhancement Program for Bipolar Disorder study, a longitudinal cohort study. Survival analysis was used to examine time to transition to mania, hypomania, or mixed state among 2166 bipolar I and II individuals in a major depressive episode. Cox regression was used to examine baseline clinical and sociodemographic features associated with hazard for such a direct transition. These features were also examined for interactive effects with antidepressant treatment. In total, 461/2166 subjects in a major depressive episode (21.3%) transitioned to a manic/hypomanic or mixed state before remission, including 289/1475 (19.6%) of those treated with antidepressants during the episode. Among the clinical features associated with greatest transition hazard were greater number of past depressive episodes, recent or lifetime rapid cycling, alcohol use disorder, previous suicide attempt, and history of switch while treated with antidepressants. Greater manic symptom severity was also associated with risk for manic transition among both antidepressant-treated and antidepressant-untreated individuals. Three features, history of suicide attempt, younger onset age, and bipolar subtype, exhibited differential effects between individuals treated with antidepressants and those who were not. These results indicate that certain clinical features may be associated with greater risk of transition from depression to manic or mixed states, but the majority of them are not specific to antidepressant-treated patients. Neuropsychopharmacology (2010) 35, 2545-2552; doi:10.1038/npp.2010.122; published online 8 September 2010

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据